Background/Aims: Recent studies have shown that circulating microRNAs (miRNAs) are emerging as promising biomarkers for cardiovascular diseases. This study aimed to determine whether miR-19b-3p, miR-134-5p and miR-186-5p can be used as novel indicators for acute myocardial infarction (AMI). Methods: To investigate the kinetic expression of the three selected miRNAs, we enrolled 18 patients with AMI and 20 matched controls. Plasma samples were collected from each participant, and total RNA was extracted. Quantitative real-time PCR and ELISA assays were used to investigate the expression of circulating miRNAs and cardiac troponin I (cTnI), respectively. Plasma samples from another age-and gender-matched cohort were collected to investigate the impact of medications for AMI on the expression of the selected miRNAs. Results: Levels of plasma miR-19b-3p, miR-134-5p and miR-186-5p were significantly increased in early stage of AMI. Plasma miR-19b-3p and miR-134-5p levels reached peak expression immediately after admission (T0), whereas miR-186-5p achieved peak expression at 4 h after T0. All of these times were earlier than the peak for cTnI (8 h after T0). In addition, all three miRNAs were positively correlated with cTnI. Receiver Operating Characteristic (ROC) analysis indicated that each single miRNA showed considerable diagnostic efficiency for predicting AMI. Furthermore, combining all three miRNAs in a panel increased the efficiency of distinguishing between patients with AMI and controls. Moreover, we found that heparin and medications for AMI did not impact the expression of these
Introduction
Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide [1] . Early and accurate diagnosis of AMI is crucial to managing the disease, circumscribing myocardial injury, and preserving heart function. Some biomarkers, such as cardiac troponins (cTnI/cTnT) and creatine kinase, have been widely used for the diagnosis of AMI during the past few decades [2, 3] . However, circulating cTnI/cTnT is not an entirely specific marker for discriminating AMI from other diseases, such as severe heart failure, viral myocarditis, takotsubo cardiomyopathy, hypothyroidism, chronic kidney failure and septic shock [4] [5] [6] [7] . Consequently, there is a clinical need for novel diagnostic biomarkers to reliably and immediately rule in or rule out AMI.
MicroRNAs (miRNAs) are a class of short (~22 nucleotide), single-stranded, non-coding RNAs that facilitate the down-regulation of gene expression by binding to complementary sequences in the 3' untranslated region (3' UTR) of target mRNAs [8] [9] [10] . Moreover, an accumulating number of miRNAs have been verified to be critically involved in maintaining normal heart function and pathological process involved in cardiovascular diseases [11] [12] [13] [14] [15] [16] [17] . In addition to being potent regulators of gene expression, recent studies have shown that miRNAs may also serve as circulating biomarkers for various diseases, including tumors and cardiovascular disorders, because of their remarkable stability in the blood, urine and other fluids [18] [19] [20] [21] .
The diagnostic value of cardiac-enriched miRNAs in the setting of AMI has been the focus of recent studies. Considering that AMI is a complex pathophysiological process with the involvement of various kinds of cells, the contribution of non cardiac-enriched miRNAs is worthy of equal attention. miR-19b is a member of the miR-17-92 cluster (miR-17/18a/19a/19b/20a/92a), which is located on chromosome 13 [22, 23] . Previous studies have shown that miR-19b is involved in aging-associated heart failure and the positive regulation of cardiomyocyte hypertrophy and apoptosis by targeting atrogin-1 and MuRF-1 [24] . As a potential plasma biomarker for the diagnosis of acute pulmonary embolism, miR-134 is also reported to be up-regulated in patients with acute coronary syndrome (ACS) [25] [26] [27] . miR-186, which is previously reported to serve as a circulating biomarker for certain cancers [28, 29] and modulate apoptosis in several kinds of cells [30, 31] , may also facilitate the diagnosis of ACS [26, 32] . Although all these miRNAs were not cardiac-enriched miRNAs, preliminary evidence from a recent miRNA microarray analysis revealed that the expression of miR-19b, miR-134 and miR-186 were up-regulated in patients with AMI compared to controls [33] . However, the specific expression patterns of these circulating miRNAs in patients with AMI, and their clinical significance remain unknown. In this study, we aim to assess the dynamic expressions of plasma miR-19b-3p, miR-134-5p and miR-186-5p at different time-points in the early stage of AMI, and to explore their diagnostic value.
Materials and Methods

Ethics Statement
The protocols used in the present study were conducted according to the principles expressed in the Declaration of Helsinki and approved by the Medical Ethics Committee of the Union Hospital of Huazhong University of Science and Technology. Patients were admitted to the Department of Cardiology in Union Hospital (Wuhan, China) between January 2013 and April 2014.
Patients
There were two cohorts from which a total of 106 participants were enrolled in our study. In addition, written informed consent was obtained from all enrolled patients, and the data for clinical presentation/ history, cardiovascular risk factors and medication records were also obtained.
We enrolled 18 patients with AMI and 20 matched control subjects in the first cohort. The inclusion criteria for AMI patients were based on the 2012 ESC/AHA/ACC guidelines [34] . Briefly, the inclusion criteria were: lasting ischemic symptoms (>30 min); increased creatine kinase-MB (CK-MB) and cTnI levels that were twice the upper limit of normal; pathological Q waves; ST-T segment and T wave changes; and coronary angiography. All of the AMI patients were diagnosed for the first time and underwent a primary percutaneous coronary intervention (PCI). Coronary angiography was performed to exclude coronary heart disease (CHD) in control subjects. The exclusion criteria were as follows: previous history of cardiac diseases (MI, heart failure or cardiomyopathy), known malignancy, renal replacement therapy, surgery or skeletal muscle damage within the previous months, all of which might impact the expression of miRNAs. Moreover, we collected blood samples before and after PCI procedures to investigate the effects of heparin on plasma miRNAs.
To further investigate whether the medications used to treat AMI, including angiotensin converting enzyme inhibitors (ACEI), beta-blockers, nitrates, statins, aspirin and clopidogrel, had an impact on the expression of plasma miRNAs, we enrolled 32 patients who were using these medications (medications were administered to patients for at least one week) and 36 matched controls in the second cohort. The exclusion criteria for the second cohort were the same as for the first cohort.
Sample collection and storage
Patients who presented with acute chest pain were admitted to Union hospital, and peripheral venous blood samples from AMI patients were obtained at each time-point as follows. The initial blood sample collection time (T0) was 10.40 ± 3.52 h after the onset of chest pain symptoms. Additionally, following T0, other blood samples were obtained at 4 h ± 30 min (4 h All blood samples (4-8 mL) were collected with K2-EDTA-coated tubes (BD, New Jersey, US). All samples were treated using the following protocol: samples were stored for up to 24 h at 4°C, and then a two-step centrifugation protocol (1,500 g for 15 min at 4°C and then 14,000 g for another 15 min at 4°C) was initiated. After centrifugation, the plasma was extracted, aliquoted, transferred to RNase/DNase-free tubes and stored at -80°C for the following experiments.
Plasma microRNA isolation and validation
Using TRIzol Reagent BD (TR126, MRC, Cincinnati, US), total RNA was extracted from plasma according to the manufacturer's instructions. Briefly, frozen plasma was thawed, and then the plasma (250 μL) was mixed with 750 μL TRIzol and incubated for 15 min at room temperature to ensure complete dissociation of nucleoprotein complexes (1/3, v/v). After chloroform was added (200 μL), the mixture was vortexed vigorously for 15 sec. After extraction at room temperature (15 min), the mixture was centrifuged at 12,000 g for 15 min at 4°C. The upper aqueous phase was transferred to fresh reagent tubes, and then an equal volume of cold isopropanol was added and the solution was incubated at -20°C overnight. All samples were centrifuged at 12,000 g for 15 min at 4°C, and the supernatant was thrown out. Then, the RNA pellet was purged with 1 mL ethanol (75% v/v) to remove residual salt. For normalization, each sample was supplemented with 25 pM Caenorhabditi selegans miR-39 (cel-miR-39) after the addition of TRIzol, as previously reported [35] .
To determine the circulating levels of miRNAs, 1 μg total RNA was reverse-transcribed using a cDNA Reverse Transcription Kit (TAKARA, Japan) according to the manufacturer's protocol. Quantitative real-time PCR (qRT-PCR) were performed using a Bulge-Loop TM miRNA qRT-PCR Detection Kit (Ribobio, Guangzhou, China) and a SYBR Green PCR Master Mix Kit (TransGen Biotech, Beijing, China) with cel-miR-39 used as the normalization control. All data were analyzed using Bio-Rad CFX Manager software (Bio-Rad, CA). Cycle threshold (Ct) values were normalized to cel-miR-39 using the formula 2- Determination of plasma cardiac troponin I levels All plasma samples used for cTnI level determination were aliquoted and stored at -80°C until further use. Subsequently, the expression level of plasma cardiac troponin I (cTnI) was determined using an immune-fluorescence diagnostics system (Abbott Diagnostics, Abbott Park, IL, USA) according to the manufacturer's directions. The normal reference range for cTnI was established to be < 0.3 ng/ml.
Statistical analysis
All data were represented as the mean ± standard deviation (SD)
Receiver operating characteristic (ROC) curves and the area under the ROC curves (AUC) were determined to discriminate AMI patients from control subjects and to assess the diagnostic accuracy of the selected miRNAs, respectively. A miRNA score (as the inverted-normalized miRNA signal) was calculated to represent the relative expression level of the selected miRNA in the AMI group compared to the control group. Importantly, the miRNA scores were calculated by deducting the normalized Ct from 40 and adjusted by subtracting the minimal score (so that the miRNA-scores started at 0), as previously reported [36] . The cut-off values with the largest Youden's index (sensitivity + specificity -1) were used to evaluate the optimal diagnostic points of the miRNAs. SPSS 13.0 software (Chicago, IL, USA) was used to perform the statistical analyses, all statistical tests were two-tailed, and p < 0.05 was considered statistically significant.
Results
Baseline characteristics of the study population
In the first cohort, we assessed the baseline characteristics of 18 AMI patients and 20 control subjects (Table 1 ). The result showed that there were no statistical differences between the control subjects and AMI patients for most of the considered clinical variables, whereas CK-MB was markedly up-regulated in the AMI patients compared to the control subjects, which is consistent with previous reports. In addition, the medications used to treat AMI were significantly different between the AMI group and the control group.
In the second cohort, which we enrolled to explore the potential effects of medications on the expression of plasma miRNAs, there were significant differences in the history of hyper-lipidemia and the application of related medications between the two matched groups ( Table 2) .
The expression patterns of circulating miRNAs
We used qRT-PCR assays to investigate the expression patterns of the selected miRNAs (miR-19b-3p, miR-134-5p and miR-186-5p) in the early phase of AMI. The results showed that the expression levels of all three miRNAs were obviously up-regulated in AMI patients compared to control subjects. The expression of circulating miR-19b-3p in AMI patients relative to the controls was increased by 5.01 ± 1.47-fold (T0), 4.27 ± 1.12-fold (4 h), 4.49 ± 1.36-fold (8 h), 3.49 ± 0.98-fold (12 h), 2.79 ± 0.86-fold (24 h), 1.87 ± 0.38-fold (48 h), and 1.51 ± 0.29-fold (72 h), respectively (Fig. 1A) . Likewise, the circulating level of miR-134-5p was increased by 6.00 ± 1.69-fold (T0), 4.19 ± 1.14-fold (4 h), 3.57 ± 1.11-fold (8 h), 3.18 ± 1.14-fold (12 h), 2.03 ± 0.29-fold (24 h), 2.25 ± 0.73-fold (48 h) and 1.62 ± 0.17-fold (72 h), respectively (Fig. 1B) . Relative to levels in the control subjects, circulating miR-186-5p was increased by 1.96 ± 0.42-fold (T0), 2.48 ± 0.45-fold (4 h), 1.83 ± 0.55-fold (8 h), 1.48 ± 0.27-fold (12 h), 1.39 ± 0.23-fold (24 h), 1.29 ± 0.15-fold (48 h), and 1.13 ± 0.08-fold (72 h), respectively (Fig. 1C) .
Meanwhile, circulating miR-19b-3p and miR-134-5p both achieved peak expression at T0; however, circulating miR-186-5p reached peak expression at 4 h after T0. Compared to Table 2 . Clinical characteristics of the enrolled subjects in the second cohort. BMI, Body mass index; DM, Diabetes mellitus; WBC, white blood cell; TC, total cholesterol; TG, total triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Cr, creatinine; ACE, angiotensin-converting enzyme. Data are shown as the mean ± SD; * p < 0.05 and ** p < 0.01 in the medication group vs. the control group Fig. 1 . The expression levels of circulating miRNAs and cTnI in AMI patients and control subjects. The expression levels of circulating miR-19b-3p (A); miR-134-5p (B); and miR-186-5p (C) in AMI patients and control subjects. The expression levels of circulating cTnI (D) in AMI patients and control subjects. AMI, acute myocardial infarction; CRTL, controls; T0, the initial time point of blood sample collection after admission. Data are shown as the mean ± SD; * p < 0.05 and ** p < 0.01 vs. control subjects. Fig. 2 . The kinetic expressions of circulating miRNAs and cTnI in AMI patients and the relationships between them. (A) the expression patterns of circulating miR-19b-3p and cTnI in the AMI group; (B) the expression patterns of circulating miR-134-5p and cTnI in the AMI group; (C) the expression patterns of circulating miR-186-5p and cTnI in the AMI group; (D) the correlation between circulating miR-19b-3p and cTnI; (E) the correlation between circulating miR-134-5p and cTnI; and (F) the correlation between circulating miR-186-5p and cTnI. AMI, acute myocardial infarction; CRTL, controls. Data are shown as the mean ± SD; # p < 0.05 vs. peak level in the AMI patients.
The expression pattern of plasma cTnI
Plasma cTnI levels were determined at different time points using the same samples that were used for the analysis of miRNAs. The results showed that the expression level of cTnI in AMI patients was increased, relative to the control subjects, by 938 ± 304-fold (T0), 1083 ± 308-fold (4 h), 1247 ± 477-fold (8 h), 1165 ± 428-fold (12 h), 645 ± 201-fold (24 h), 412 ± 156-fold (48 h) and 245 ± 77-fold (72 h), respectively (Fig. 1D) . In addition, plasma cTnI levels achieved peak expression at 8 h after T0, which was later than the peak for miR19b-3p, miR-134-5p and miR-186-5p.
The correlation between circulating miRNAs and cTnI Then, we investigated the relationship between plasma miRNA and cTnI levels. The results indicated that all three selected circulating miRNAs, miR-19b-3p (r = 0.61) miR-134-5p (r = 0.55) and miR-186-5p (r = 0.51), exhibited a significantly positive correlation with cTnI ( Fig. 2A-2F ).
The diagnostic specificity and sensitivity of miRNAs in AMI To further explore the applicability of using circulating miRNAs as potential diagnostic biomarkers for AMI, we converted the expression levels of the miRNAs into miRNA scores and performed ROC analysis, as previously reported. we demonstrated that circulating miR-19b-3p, miR-134-5p and miR-186-5p may serve as novel candidate diagnostic biomarkers at the early stage of AMI.
proliferator-activated receptor γ coactivator 1α (PGC-1α) during the progression of atherosclerosis and that it promotes macrophage cholesterol accumulation, foam cell formation and aortic atherosclerotic development by targeting ATP-binding cassette transporter A1 (ABCA1) [42, 43] . In addition, miR-19b has been found to be upregulated in plasma of unstable angina pectoris (UAP) patients, and may play an anti-thrombotic role by targeting tissue factor (TF) [44] , which is an essential pro-coagulant protein. Immunity is another well established regulator of acute coronary events [41] , and previous studies have shown that the miR-17-92 cluster also plays crucial roles in regulating various immune responses by promoting CD4+ T cell activation, proliferation, survival, Th1 differentiation and Th17-mediated inflammation, while inhibiting Th2 and iTreg differentiation [45] [46] [47] [48] . miR-134 had been reported to be a brain-specific miRNA, and regulate ischemia/reperfusion injury-mediated neuronal cell death by targeting heat shock protein A12B (HSPA12B) and cyclic AMP response element-binding protein (CREB) [49, 50] . Interestingly, recent studies indicated that miR-134 might be used as a potential biomarker of coronary artery calcification, UAP or AMI [51] . Furthermore, recently published studies showed that miR-186 was up-regulated in AMI or UAP patients, and may have potential diagnostic value in combination with a few other miRNAs [26, 32] . Collectively, existed evidence implies that miR-19b may play pivotal roles in the course of ACS/AMI. However, the contributions of miR-134 and miR-186 in the process of AMI remain largely unexplored. Therefore, further studies would be necessary to investigate whether studied miRNAs are mechanistically involved in AMI, apart from their roles as circulating biomarkers.
There are some limitations to our present study. Firstly, the study involves a relatively small sample size, and larger clinical studies will be needed in the future to confirm the diagnostic value of miR-19b-3p, miR-134-5p and miR-186-5p for AMI. Secondly, given that ACS encompasses the clinical entities of AMI and UAP, which represent different progressive stages on the same pathological substrates, therefore, it would remain to be elucidated by future studies whether studied miRNAs could further discriminate between AMI and other acute coronary conditions. In addition, it has been recently discovered that exosomemediated transfer of miRNAs may be involved in cell-to-cell communication [20, 52, 53] . However, the underlying functions of these three selected circulating miRNAs in intracellular communication and their possible roles in the pathophysiological processes of AMI remain unknown.
In summary, our present study investigated, for the first time, the dynamic expressions of circulating miR-19b-3p, miR-134-5p and miR-186-5p in the early phase of AMI. ROC analysis suggested that circulating miR-19b-3p, miR-134-5p and miR-186-5p may be considered novel and promising biomarkers for early diagnosis of AMI. Moreover, a multi-miRNA panal including these three selected miRNAs may present even greater diagnostic value for AMI.
